• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES EDWARDS INTUITY ELITE VALVE SYSTEM; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES EDWARDS INTUITY ELITE VALVE SYSTEM; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Model Number 11000A29MM
Device Problem Gradient Increase (1270)
Patient Problems Aneurysm (1708); Heart Failure/Congestive Heart Failure (4446)
Event Date 01/10/2022
Event Type  Injury  
Manufacturer Narrative
Additional manufacturer narrative: the investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
 
Event Description
It was reported from the commence trial that a patient with a 29mm 11000a pericardial aortic valve aortic underwent explant after implant duration of 6 years, 5 months due to aortic valve stenosis, halt, and decreased mobility of the left cusp.The patient presented with chf, class 11 nyha symptoms.The explanted 29mm 11000a aortic valve was replaced with a 29mm 3300tfx pericardial valve.The patient was discharged home on pod #8.Per medical source documents the patient presented for ascending aortic root, ascending aortic arch aneurysm as well as redo avr.Halt was listed as an indication for surgery, findings at surgery indicated decreased mobility of the left cusp.The post op diagnosis in the op note indicated severe halt.The patient underwent redo avr with a 29mm pericardial magna valve, transverse aortic arch repair with a 30mm graft and ascending aortic aneurysm repair with a 30mm dacron graft.The post op tee showed lvef 60%.The patient tested positive for covid-19 in hospital and was asymptomatic.The patient was discharged on coumadin.
 
Manufacturer Narrative
Manufacturer narrative: updated sections: d4 expiration date, g3, g6, h4, h6 component code, type of investigation, investigation findings, and investigation conclusions.The device history record was reviewed and shows that this device met all manufacturing specifications for product release prior to distribution.No issues were identified that would have impacted this event.On occasion the device may be explanted with no evidence of malfunction and is otherwise performing as intended.Such as for aortic graft replacement, to enlarge aortic root, repair fistula, control bleeding/coagulopathy or other non-device related reason.In these events, the device may require removal to control bleeding or to facilitate repair of the injury.The event is not related to the device.Through further investigation, it was determined that the root cause of this event was most likely due to procedural factors.H11 corrected data: sections: b5, b7, d6b.And h6 health effect - clinical code.Based on the additional information, this event is no longer considered reportable.
 
Event Description
It was reported from the commence trial that a patient with a 29mm 11000a pericardial aortic valve aortic underwent explant after implant duration of 6 years, 5 months prophylactically during a procedure to repair ascending aortic, and aortic arch aneurysm.The explanted valve was replaced with a 29mm 3300tfx pericardial valve.The patient was discharged home on pod #8.Per medical records, the patient is a know case of ascending aortic, and aortic arch aneurysm.The patient presented with acute on chronic heart failure secondary to the enlarged aneurysm.The patient underwent aortic arch and ascending aortic aneurysm repair using a 30mm graft conduit.Due to the age of the bioprosthetic valve and the previous history of halt, the surgeon decided to redo the avr using redo avr.A 29mm 3300tfx pericardial valve was implanted in replacement.Post op tee showed well-seated and normally functioning replacement valve.The patient tested positive for covid-19 in hospital and was asymptomatic.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EDWARDS INTUITY ELITE VALVE SYSTEM
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer (Section G)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer Contact
saurav singh
1 edwards way
irvine, CA 92614
9492506615
MDR Report Key16439075
MDR Text Key310191940
Report Number2015691-2023-11082
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P150048
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Study,Health Professional
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 04/24/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/24/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Expiration Date03/29/2016
Device Model Number11000A29MM
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received04/04/2023
Date Device Manufactured02/26/2015
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Life Threatening; Hospitalization;
Patient Age66 YR
Patient SexMale
-
-